How longevity, senolytic, partial-reprogramming, and geroscience startups raise capital in 2026 amid Altos, Retro, NewLimit.
Longevity therapeutics moved from wellness pitch decks to real clinical programs. Altos Labs (~$3B), Retro Biosciences (~$180M), NewLimit (~$140M), Life Biosciences, Rejuvenate Bio, BioAge (IPO then Phase 2 termination), Loyal (dog aging), Cambrian Bio, Turn Biotechnologies, Iambic-adjacent, Gordian Biotechnology, and Fauna Bio raised as partial-reprogramming, senolytics, and geroscience produced credible clinical candidates. FDA held workshops on aging biomarkers and the TAME trial framework. Investors want either a specific age-related indication with FDA-approvable endpoints (obesity + muscle, fibrosis, IPF, Alzheimer's, osteoarthritis, sarcopenia) or a platform with defensible IP — not 'we will cure aging' pitches.
Partial-reprogramming programs entered clinic or IND-enabling stage. Retro Biosciences (Sam Altman-backed) advanced multiple programs. NewLimit raised $130M B. Altos continued but with talent turnover. BioAge terminated azelaprag Phase 2 - a cautionary tale. GLP-1 drugs (Ozempic, Mounjaro, Zepbound) restructured obesity + aging conversations - muscle preservation, sarcopenia, and metabolic-aging markets accelerated. FDA held aging biomarker workshops. Loyal completed FDA effectiveness evaluation for dog aging drug (LOY-002). Rejuvenate Bio advanced gene therapy programs. Turn Biotechnologies advanced mRNA reprogramming.
Seed: $5-30M. Series A: $30-100M. Series B: $80-300M. Reference: Altos (~$3B seed), Retro (~$180M seed), NewLimit (~$140M A+B), Life Bio (~$50M+ raised), Rejuvenate Bio (~$45M+ raised), BioAge (IPO ~$200M+ pre + $200M IPO, azelaprag terminated), Loyal (~$125M+ raised), Cambrian Bio (~$100M+ raised), Turn (~$25M+ raised), UBX (public, Phase 2 setbacks), Gordian ($55M+ raised). Category is capital-intensive but attracts unusual patient capital from tech-billionaire LPs.
'Cure aging' pitches without FDA-approvable indication. Repurposed generics (rapamycin, metformin) without IP. Weak biomarker + endpoint strategy. Overreliance on epigenetic clocks as clinical endpoints (FDA does not accept them). Missing KOL relationships. Underestimating Phase 2 risk (BioAge lesson). No pharma partnership by Series B.
Investor directory · Fundraising library · Articles A–Z · Company funding database